The US FDA’s new limited population pathway for antimicrobials may have given Insmed Inc. the help it needed to get its lung disease drug Arikayce to market amid agency uncertainties about surrogate endpoint reliability and clinical benefit.
On Sept. 28, FDA granted accelerated approval to Arikayce (amikacin liposome inhalation suspension) for the treatment of Mycobacterium avium complex...






